erlotinib hydrochloride has been researched along with thiophenes in 4 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (thiophenes) | Trials (thiophenes) | Recent Studies (post-2010) (thiophenes) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 17,012 | 1,961 | 8,038 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, C; Durkin, AJ; Osborne, DA; Rosemurgy, AS; Yeatman, TJ; Zervos, EE | 1 |
| Epstein, D; Haley, JD; Petti, F; Sujka-Kwok, I; Thomson, S | 1 |
| Brock, K; Evans, TR; Gedrich, R; Hopkins, CA; Macpherson, IR; Poondru, S; Simon, GR; Stephens, A; Stewart, K | 1 |
| Bender, C; Fichtner, I; Fröhlich, H; Herwig, R; Hülsmann, HJ; Jarahian, M; Korf, U; Kuner, R; Merk, J; Rolff, J; Sültmann, H; Thomas, M | 1 |
1 trial(s) available for erlotinib hydrochloride and thiophenes
| Article | Year |
|---|---|
A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Quinolines; Thiophenes; Tissue Distribution | 2013 |
3 other study(ies) available for erlotinib hydrochloride and thiophenes
| Article | Year |
|---|---|
EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cell Division; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phenylalanine; Protease Inhibitors; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Thiophenes | 2006 |
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Topics: Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Chromatography, Liquid; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoblotting; Lung Neoplasms; Mesoderm; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Respiratory Mucosa; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Spectrometry, Mass, Electrospray Ionization; Thiophenes; Transforming Growth Factor beta; Tumor Cells, Cultured | 2008 |
Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Enzyme Activation; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Pyrones; Quinazolines; Signal Transduction; Thiophenes; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |